Community Support Colorectal Cancer
A newly opened endoscopy suite at Salud Family Health in Longmont highlights the importance of longstanding partnerships between the University of Colorado Cancer Center and community stakeholders in supporting underserved populations who otherwise might not receive vital cancer screening services.
Research Support Cancer Funding
University of Colorado Cancer Center researchers from the Anschutz and Boulder campuses are collaborating on a broad range of research that recently received AB Nexus support.
Research Community Support Magazine Multiple Myeloma
Michael Joseph Roark – Mike to his friends – met Mary Jo Dougherty in a ski fitness class taught by Anne Kashiwa at the former International Athletic Club in downtown Denver.
Patient Care Community Support Cancer
National Cancer Survivors Day, June 6, 2021, is a day to recognize cancer survivors, bring attention to the ongoing challenges cancer survivors face, and celebrate life.
At the University of Colorado (CU) Cancer Center, we use awareness months and days to highlight and honor our patients – both past and present – that have fought these cancers, as well as educate about warning signs, new treatments, clinical trials, prevention methods, and support options.
During the COVID-19 pandemic patients with cancer may be experiencing mental health challenges such as increased anxiety or depression. The psycho-oncology team at the CU Cancer Center is providing tips that can help during these difficult times.
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.
Rachel Sauer
